Introduction
============

Nasopharyngeal carcinoma (NPC) is a type of malignant tumor of the head and neck, which is prevalent in South China and Southeast Asia [@B1], with an annual incidence of approximately 20 to 30 per 100,000 [@B2]. Due to its specific anatomical location and sensitivity to radiation, radiotherapy is the mainstay treatment modality for NPC [@B3]. In recent years, the revolution from two-dimensional conventional radiotherapy (2DCRT) to intensity-modulated radiotherapy (IMRT) has improved the outcome of NPC [@B4]. For early-stage of NPC (T1N0M0), radiotherapy alone is the mainstay treatment modality. However, approximately 70% of newly diagnosed NPC patients present with locoregionally advanced disease, which are more likely to develop local recurrence and distant metastasis when treated with radiotherapy alone [@B5]. Several clinical trials have verified the cisplatin-based concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced NPC [@B6], [@B7]. However, CCRT is insufficient for patients with high-risk factors, such as bulky tumors and/or extensive nodal disease, which has higher potential for distant metastasis [@B8].

In order to improve the outcome of locally advanced NPC patients, several studies were carried out to evaluate the efficacy of neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy (ACT) in combination with CCRT [@B9]-[@B11]. Hui et al [@B9] indicated that NACT plus CCRT has improved 3-year overall survival (OS) than CCRT alone in stage III to IVB NPC patients (94% VS 67.7%, *P*=0.012). Chen et al [@B12] also found the similar results. Unfortunately, the conflicting findings of the studies by other researchers made the benefit undetermined [@B10], [@B13]. Consequently, the role of NACT is still uncertain and need to be confirmed by more research.

Although the regimen of 5-fluorouracil (5-FU) plus cisplatin (CDDP) has been widely used as the standard treatment for NPC, CDDP is well-known for its side effects such as kidney dysfunction and digestive disorders. In order to relieve these side effects caused by CDDP, a second-generation cisplatin analog, nedaplatin (NDP) is developed [@B14]. Compared with CDDP, NDP has a different molecular structure but similar anticancer potencies, which is associated with a lower incidence of severe digestive symptoms and renal toxicity. Furthermore, numerous studies have indicated that NDP has wildly used in many kinds of tumors for its efficacy and safety, such as esophageal cancer [@B15], non-small cell lung cancer [@B16], uterine cervix cancer [@B17], and some head and neck squamous cell carcinoma [@B18], [@B19]. To date, the research of NDP versus CDDP in locally advanced NPC is mainly on the short-term efficacy and toxicity, but lack of the long-term survival outcome [@B20]. Recently, Tang et al [@B21] performed an open-label, non-inferiority, randomised phase 3 trial to confirmed that nedaplatin-based concurrent chemoradiotherapy represents an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy for patients with locoregional, advanced nasopharyngeal carcinoma. However, they did not explore the potential use of nedaplatin-based chemotherapy as neoadjuvant chemotherapy. Therefore, we performed this retrospective study to determine the efficacy, toxicity and long-term outcome of neoadjuvant chemotherapy with fluorouracil plus NDP or CDDP combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Materials and Methods
=====================

Patients
--------

Between January 2009 and November 2011, 195 pathologically confirmed locally advanced NPC in Zhejiang Cancer Hospital who received neoadjuvant chemotherapy with fluorouracil plus NDP or CDDP combined with concurrent chemoradiotherapy were retrospectively reviewed. Inclusion criteria was as follows: Pathologically confirmed NPC with Stage III - ⅣB according to the AJCC 2010 staging system[@B22], there is no evidence of distant metastasis, no uncontrolled medical or psychiatric disease, while the patients were free from any previous malignancy or other concomitant malignant diseases, and Karnofsky Score ≥70. Prior to treatment, all patients had undergone a complete history and physical examination, complete blood cell count, comprehensive serum chemistry profile, electrocardiogram (ECG), fiber-optic nasopharyngoscopy and biopsy, chest X-ray or computed tomography(CT), ultrasonography of the abdomen or computed tomography(CT), bone scan and magnetic resonance imaging (MRI) of the head and neck region. Among the 195 patients, 9 patients were excluded due to limited follow-up information. As a result, a total of 186 patients were left for analysis. Patient and disease characteristics are listed in Table [1](#T1){ref-type="table"}. This study was approved by the Research Ethics Committee of Zhejiang Cancer Hospital.

Radiotherapy
------------

All patients were treated with IMRT using a 6MV X-ray. Briefly, gross tumor volume of nasopharynx (GTVnx) included the primary tumor and positive retropharyngeal lymph nodes were determined based on clinical and imaging examinations. Metastatic cervical lymph nodes were defined as gross tumor volume of involved cervical lymph nodes (GTVnd). The high-risk region was delineated as clinical target volume (CTV1), which included the GTVnx and GTVnd with a margin of 5-10mm, entire nasopharynx, inferior two-thirds of the sphenoid sinus, the anterior third of the clivus, pterygoid fossae, posterior third of nasal cavity and maxillary sinuses, retropharyngeal nodes, parapharyngeal space, and the drainage of the upper neck. Low risk region was defined as CTV2, which included CTV1 plus a margin of 3-5 mm, the lower neck and the supraclavicular lymphatic drainage region. The planning target volume (PTV) was defined as the area from 3-5mm outside the CTV or GTV. The dose prescribed was as follows: 66-70 Gy to the GTVnx PTV and 66-70 Gy to the GTVnd PTV, 60 Gy to the CTV1 PTV, 54 Gy to the CTV2 PTV. The total dose of the GTVnx PTV, GTVnd PTV, CTV1 PTV and CTV2 PTV was given in 30-33 fractions. Furthermore, according to the Radiation Therapy Oncology Group 0225 protocol [@B23], maximum dose of each organ at risk (OAR) was below its tolerance limit. All patients received one fraction daily for five days per week. Pinnacle version 7.6 planning system was used to design all the plans.

Chemotherapy
------------

In the PF group, neoadjuvant chemotherapy regimen comprised 75mg/m^2^ of CDDP on day 1 and 800mg/m^2^/d of 5-fluorouracil for continuous intravenous infusion 120 hours in a cycle of 21 days for 2 to 3 cycles, followed by IMRT concurrent with CDDP at a dose of 80mg/m^2^ altogether for 3 days in a cycle of 21 days for 2 to 3 cycles or weekly intravenous CDDP at 40mg/m^2^ for up to 6 cycles. In the NF group, the neoadjuvant chemotherapy regimen comprised 75mg/m^2^ of NDP on day 1 and 800mg/m^2^/d of 5-fluorouracil for continuous intravenous infusion 120 hours in a cycle of 21 days for 2 to 3 cycles, followed by IMRT concurrent with NDP at a dose of 80mg/m^2^ every 3 weeks for 2 to 3 cycles or 40mg/m^2^ NDP weekly for up to 6 cycles.

Follow-up and treatment assessment
----------------------------------

Treatment induced toxicities were scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. All patients were evaluated weekly during the treatment, and regularly followed up in our hospital after completion of the treatment once every 3 months in the first 2 years, once every 6 months from the third to the fifth years, and then once every year thereafter until death or their last follow-up appointment. The endpoint of the final follow-up was December 2017, and the median follow-up period was 68 months (ranging from 16 to 97 months). The patients who failed to meet follow-up requirements more than twice were excluded. Actually, our follow-up assessments consist of patient history, physical examination, fiber-optic nasopharyngoscopy and biopsy, chest X-ray or CT, ultrasonography of the abdomen or CT, and MRI examination for the head and neck. Furthermore, when the patients showed the symptoms of bone pain, whole-body bone scan would be performed.

Statistical Analysis
--------------------

Statistical analyses were performed using SPSS v18.0 software (SPSS, Chicago, IL, USA). Characteristics of patients were compared via chi-square test or Fisher\'s exact test. The Kaplan-Meier method was used to calculate the overall survival (OS) rate, local relapse-free survival (LRFS) rate, regional relapse-free survival (RRFS) rate, distant metastasis-free survival (DMFS) rate and progression-free survival (PFS) rate. Multivariate analysis was estimated using the Cox proportional hazards model. Two-sided *P* values \<0.05 were considered to be statistically significant.

Results
=======

**Patien**t Characteristics
---------------------------

The patients and disease characteristics of 186 cases are listed in Table [1](#T1){ref-type="table"}. Among the 186 patients, 103 patients were included in the NF group and 83 patients were included in the PF group. According to the AJCC 2010 staging system, patients in our research were divided into stage III (123 patients; 66.1%), stage ⅣA (34 patients; 18.3%) and stage ⅣB (29 patients; 15.6%). Between the two groups, there were no statistically significant differences of the proportional distribution of age (≤50 vs \>50), sex, histology, T stage, N stage, AJCC clinical stage and cycle of neoadjuvant chemotherapy (all P value\>0.05).

Efficacy
--------

The tumor response three months after completion of therapy in the two groups were depicted in Table [2](#T2){ref-type="table"}. Responses were classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), according to the RECIST criteria. As for the response of primary tumor, 97 cases (94.2%) of CR and 6 cases (5.8%) of PR in the NF group, while 80 cases (96.4%) of CR and 3 cases (3.6%) of PR in the PF group. As for the response of nodes, 90 cases (87.4%) of CR and 13 cases (12.6%) of PR in the NF group, versus 70 cases (84.3%) of CR and 13 cases (15.7%) of PR in the PF group. There was no significant difference in CR rate either in the response of primary tumor or the response of nodes between the two groups (all *P* value\>0.05).

Acute Toxicity
--------------

Acute toxicities were assessed between the two groups and are summarized in Table [3](#T3){ref-type="table"}. In the NF group, 67 patients (65%) had grade 0-2 leucopenia, 36 (35%) had grade 3-4. While 53 patients (63.9%) in the PF group had grade 0-2 leucopenia, and 30 (36.1%) had grade 3-4. There were no significant differences between the two groups (*P*=0.866). However, more patients in the NF group suffered from grade 3-4 neutropenia and grade 3-4 thrombocytopenia than those in the PF group (46.6% vs 31.3%, *P*=0.035 and 17.5% vs 7.3%, *P*=0.042, respectively). While it was common to suffer from nausea, vomiting and weight loss for patients in the PF groups with P values of \<0.001 and 0.025, respectively. There were no significantly differences between the two groups in anemia, dermatitis, stomatitis (mucositis), xerostomia, liver or kidney dysfunction, hypokalemia or hyponatremia, with all P value \>0.05.

**Surviv**al outcomes
---------------------

For the 186 patients in our study, the median follow-up period was 68 months (ranging from 16 to 97 months). As shown in Figure [1](#F1){ref-type="fig"} and Table [4](#T4){ref-type="table"}, 5-year OS, PFS, LRFS, RRFS and DMFS rates did not differ significantly between NF and PF groups (OS: 82.4 % vs 79.4%, *P* =0.575; PFS: 72.6% vs 68.7%, *P*=0.469; LRFS: 86.2% vs 92.6%, *P* =0.211; RRFS: 91.0% vs 87.7%, *P* =0.485; DMFS: 80.7% vs 77.0%, *P* = 0.369).

**Progno**stic factors
----------------------

To determine which factors affected patient outcome, we used univariate analyses to evaluate the prognostic value of gender, age, histology, T stage, N stage, overall stage, regimen group and cycle of neoadjuvant chemotherapy (Table [4](#T4){ref-type="table"}). The outcomes showed that 5-year OS, PFS, RRFS and DMFS of patients with N0-1 stage were superior to those of N2-3 stage (OS: 94.8 % vs 74.8%, P =0.002; PFS: 89.6% vs 62.2%, P \<0.001; RRFS: 98.2% vs 85.6%, P =0.009; DMFS: 98.3% vs 70.3%, P \<0.001), and patients with clinical stage Ⅳ were inferior to those patients with stage III (OS: 63.2 % vs 90.2%, P\<0.001; PFS: 56.8% vs 78.0%, P=0.002; LRFS: 80.4% vs 93.3%, P =0.008; DMFS: 62.3% vs 87.3%, P\<0.001). In multivariate analysis (Table [5](#T5){ref-type="table"}), N stage was an independent factor for OS, PFS, RRFS and DMFS.

Discussion
==========

Our research is a retrospective analysis for the treatment of locally advanced NPC with PF or NF regimen neoadjuvant chemotherapy combined with concurrent chemoradiotherapy. Compared with the PF group, the NF group showed a similar efficacy in the tumor response rate. As shown in table [2](#T2){ref-type="table"}, there were no significant differences in CR rate both in the response of primary tumor and nodes between the two groups. In the present study, we also found that the PF group and the NF group had similar survival outcomes. The 5-year OS, PFS, LRFS, RRFS, and DMFS rates did not differ significantly between the two groups. In terms of acute toxics effects, the PF group suffered higher incidents of grade 3 to 4 nausea, vomiting and weight loss than the NF group, while the incidences of neutropenia and thrombocytopenia were lower in the PF group. Among the potential prognostic factors examined, we indicated that N stage were independent prognostic factors of outcome.

Cisplatin-based NACT or CCRT combined with IMRT can achieve better clinical outcome than radiotherapy alone and has being the standard treatment for locally advanced NPC [@B6], [@B7], [@B9], [@B24]. The main treatment failure pattern is distant metastasis [@B25]. Ferrari et al [@B26] reported that long-term outcome of locoregionally advanced nasopharyngeal carcinoma patients treated with cisplatin-based induction chemotherapy and current chemoradiotherapy. The 3-year overall survival and progression-free survival rates are 80.0% and 54.0%, respectively. Wu et al [@B27] performed a prospective, multicenter clinical study to evaluate the long-term outcome in III-IVb NPC patients treated with IMRT with concurrent CDDP chemotherapy. The 5-year actuarial rates of OS, LRFS, RRFS, and DMFS were 78.4%, 86.8%, 88.4%, and 78.0%, respectively. Xu et al [@B28] demonstrated that the 3-year LRFS, DMSF, PFS and OS rates were 90.3%, 79.7%, 77.3%, and 81.6% for the locoregionally advanced NPC patients treated with concurrent chemoradiotherapy with NDP plus fluorouracil. In our study, we observed the similar results. The 5-year OS, PFS, LRFS, RRFS and DMFS in the NF and PF groups were 82.4 % vs 79.4%, 72.6% vs 68.7%, 86.2% vs 92.6%, 91.0% vs 87.7%, 80.7% vs 77.0%, respectively. Furthermore, According to our results, N stage was an independent factor for OS, PFS, RRFS and DMFS, which was comparable to the results published by Lin et al [@B29] and Lai et al [@B30].

In terms of the non-hematological toxicities, the PF group resulted in a higher frequency of grade 3 to 4 nausea and vomiting than the NF group (0% vs. 13.3%, *P*\<0.001). According to the previous studies, the incidences of severe digestive toxicity was about 27.3%-32.1% in cisplatin-based chemoradiotherapy [@B31], [@B32]. Our research revealed a much lower frequency of moderate to severe nausea and vomiting, it might due to the use of new generation of antiemetic drugs and better supportive care. Furthermore, we found that the incidence of grade 3-4 weight loss is higher in the PF group than in the NF group (4.8% vs 0%, *P*=0.025), which might be related with the gastrointestinal toxicities caused by CDDP. Additionally, another remarkable side effect of CDDP is renal toxicity. However, in our research, we did not observe grade 3-4 renal toxicity in both groups, which may due to the use of pre- and post-hydration and divide the dose of CDDP into 3 days. With respect to the hematological toxicities, the NF group resulted in a higher frequency of grade 3 to 4 neutropenia (46.6% vs. 31.3%, P=0.035) and thrombocytopenia (17.5% vs. 7.3%, P=0.042) compared with the PF group, which is higher than those reported by Cao et al [@B20]. Lee et al [@B32] reported that the dose-limiting toxicity of NDP is bone marrow suppression, however, it was reversible and transient. Furthermore, thrombopoietin (TPO) and granulocyte-colony stimulating factor (G-CSF) were used when patients had bone marrow suppression. Thus, there were no treatment-related deaths in both groups in the current study.

In conclusion, our study demonstrated that neoadjuvant chemotherapy with 5-FU plus NDP combined with concomitant NDP and IMRT achieved comparable clinical outcome to those of cisplatin-based regiments, whereas the side effect is mild and acceptable. Therefore, neoadjuvant chemotherapy with 5-FU plus NDP combined with concomitant NDP and IMRT might be an effective and safe choice for patients with locally advanced NPC. As our research is a retrospective study with small sample, which may have many limitations, we are looking forward to have more well-designed, randomized, prospective, and large sample clinical research in the future.
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###### 

Patient and disease characteristics

  Characteristic   NF (n=103)   PF (n=83)    *P* value
  ---------------- ------------ ------------ -----------
  Age (years)                                0.933
  ≤50              54 (52.4%)   43 (51.8%)   
  \>50             49 (47.6%)   40 (48.2%)   
  Gender                                     0.783
  Male             65 (63.1%)   54 (65.1%)   
  Female           38 (36.9%)   29 (34.9%)   
  Histology                                  0.931
  WHO I            17 (16.5)    13 (15.7)    
  WHO II           14 (13.6)    10 (12.0)    
  WHO III          72 (69.9)    60 (72.3)    
  T stage                                    0.542
  T1               7 (6.8%)     3 (3.6%)     
  T2               14 (13.6%)   8 (9.6%)     
  T3               59 (57.3%)   55 (66.3%)   
  T4               23 (22.3%)   17 (20.5%)   
  N stage                                    0.172
  N0               14 (13.6%)   5 (6.0%)     
  N1               20 (19.4%)   19 (22.9%)   
  N2               50 (48.5%)   49 (59.0%)   
  N3               19 (18.4%)   10 (12.0%)   
  AJCC stage                                 0.488
  III              66 (64.1%)   57 (68.7%)   
  IVA              18 (17.5%)   16 (19.3%)   
  IVB              19 (18.4%)   10 (12.0%)   
  NAC cycle                                  0.702
  1                17 (16.5)    12 (14.5)    
  2-3              86 (83.5)    71 (85.5)    

NF, nedaplatin combined with 5-fluorouracil neoadjuvant chemotherapy; PF, cisplatin combined with 5-fluorouracil neoadjuvant chemotherapy; NAC, neoadjuvant chemotherapy.

###### 

Tumor response three months after chemoradiotherapy in PF or NF group

       Response of primary tumor (%)   χ^2^      *P*     Response of nodes (%)   χ^2^        *P*                 
  ---- ------------------------------- --------- ------- ----------------------- ----------- ----------- ------- -------
  NF   97 (94.2)                       6 (5.8)   0.488   0.485                   90 (87.4)   13 (12.6)   0.354   0.552
  PF   80 (96.4)                       3 (3.6)                                   70 (84.3)   13 (15.7)           

CR, complete response; PR, partial response.

###### 

Frequency of acute toxicities from the two groups by type and grade

  Acute Toxicities         NF            PF          Z            *P*                 
  ------------------------ ------------- ----------- ------------ ----------- ------- -------------
  **Hematologic**                                                                     
  Leucopenia               67 (65.0)     36 (35.0)   53 (63.9)    30 (36.1)   0.169   0.866
  Neutropenia              55 (53.4)     48 (46.6)   57 (68.7)    26 (31.3)   2.110   **0.035**
  Thrombocytopenia         85 (82.5)     18(17.5)    76 (92.7)    6 (7.3)     2.037   **0.042**
  Anemia                   103 (100.0)   0 (0.0)     83 (100.0)   0 (0.0)     0.000   1.000
  **Non-Hematologic**                                                                 
  Vomiting                 103 (100.0)   0 (0.0)     72 (86.7)    11 (13.3)   3.799   **\<0.001**
  Nausea                   101 (98.1)    2 (1.9)     63 (75.9)    20 (24.1)   4.638   **\<0.001**
  Weight loss              103 (100.0)   0 (0.0)     79 (95.2)    4 (4.8)     2.246   **0.025**
  Dermatitis               95 (92.2)     8 (7.8)     80 (96.4)    3 (3.6)     1.190   0.234
  Stomatitis (mucositis)   90 (87.4)     13 (12.6)   74 (89.2)    9 (10.8)    0.372   0.710
  Xerostomia               101 (98.1)    2 (1.9)     83 (100.0)   0 (0.0)     1.273   0.203
  Liver dysfunction        98 (95.1)     5 (4.9)     77 (92.8)    6 (7.2)     0.681   0.496
  Kidney dysfunction       103 (100.0)   0 (0.0)     83 (100.0)   0 (0.0)     0.000   1.000
  Hypokalemia              103 (100.0)   0 (0.0)     81 (97.6)    2 (2.4)     1.580   0.114
  Hyponatremia             103 (100.0)   0 (0.0)     82 (98.8)    1 (1.2)     1.114   0.265

###### 

Effect of prognostic factors on survival in univariate analysis

  Factors         5y-OS                 5y-PFS          5y-LRFS          5y-RRFS (%)               5y-DMFS                                
  --------------- ------- ------------- -------- ------ ------------- -- ------------- ----------- --------- ------ ----------- -- ------ -------------
  Gender                  0.635                         0.186                          0.945                        0.270                 0.210
  Male            79.6                           67.7                    88.8                                88.1                  75.9   
  Female          83.6                           76.1                    89.2                                92.0                  84.2   
  Age (years)             0.939                         0.678                          0.515                        0.473                 0.938
  ≤50             81.3                           71.9                    90.5                                88.3                  78.7   
  \>50            80.8                           69.6                    87.3                                90.8                  79.2   
  Histology               0.945                         0.782                          0.148                        0.885                 0.585
  WHO I           80.0                           70.0                    79.7                                89.5                  78.3   
  WHO II          83.3                           75.0                    87.1                                91.6                  87.5   
  WHO III         80.9                           70.1                    91.4                                89.1                  77.4   
  T stage                 0.334                         0.329                          0.790                        0.103                 0.579
  T1-2            87.4                           61.5                    90.4                                81.0                  72.6   
  T3-4            79.7                           73.0                    88.6                                91.3                  80.2   
  N stage                 **0.002**                     **\<0.001**                    0.241                        **0.009**             **\<0.001**
  N0-1            94.8                           89.6                    93.0                                98.2                  98.3   
  N2-3            74.8                           62.2                    87.1                                85.6                  70.3   
  Overall stage           **\<0.001**                   **0.002**                      **0.008**                    0.115                 **\<0.001**
  III             90.2                           78.0                    93.3                                91.7                  87.3   
  ⅣA and ⅣB       63.2                           56.8                    80.4                                84.9                  62.3   
  Regimen                 0.575                         0.469                          0.211                        0.485                 0.369
  NF group        82.4                           72.6                    86.2                                91.0                  80.7   
  PF group        79.4                           68.7                    92.6                                87.7                  77.0   
  NAC cycle               0.226                         0.230                          0.171                        0.472                 0.319
  1               89.5                           78.2                    96.3                                93.0                  84.9   
  2-3             79.5                           69.4                    87.6                                88.8                  77.7   

OS, overall survival; PFS, progression-free survival; LRFS, local relapse-free survival; RRFS, regional relapse-free survival; DMFS, distant metastasis-free survival; NAC, neoadjuvant chemotherapy.

###### 

Impact of prognostic factors on treatment results by multivariate analysis (P value)

  Factors           5y-OS       5y-PFS      5y-LRFS   5y-RRFS     5y-DMFS
  ----------------- ----------- ----------- --------- ----------- -----------
  Gender                                                          
  Male vs. Female   0.929       0.323       0.949     0.404       0.423
  Age                                                             
  ≤50 vs. \>50      0.667       0.354       0.515     0.685       0.525
  Regimen                                                         
  NF vs. PF         0.630       0.534       0.211     0.550       0.425
  T stage                                                         
  T1-2 vs. T3-4     0.077       0.832       0.790     0.467       0.496
  N stage                                                         
  N0-1 vs. N2-3     **0.006**   **0.001**   0.241     **0.031**   **0.004**

OS, overall survival; PFS, progression-free survival; LRFS, local relapse-free survival; RRFS, regional relapse-free survival; DMFS, distant metastasis-free survival.
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